Skip to main contentAI and Advanced
/
AARTIPHARM · NSEMarket ticker unavailable · configure an authorised index feed
AA
NSE · Equity shares · Biotechnology & Drugs20.85 · 2.63%
Aarti Pharmalabs AARTIPHARM
NSE:INR 812.45
BSE:INR 691.45
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for AARTIPHARM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 791.6
Day rangeINR 765 — INR 819.8
52-week rangeINR 585 — INR 946.1
Volume3.79 L
Market cap6,302.24
P/E28.53
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,819.44
Net Income (INR Cr)174.71
P/E Ratio28.53
Book Value220.69
EPS19.48
Price/BV3.68Computed
Research path: Interpret Aarti Pharmalabs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
AARTIPHARMAarti Pharmalabs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,481.71 | 2,902.43 | 2,582.11 |
| Cash Equivalents | 8.53 | 6.73 | Not available |
| Other Liabilities Total | 7.85 | 8.12 | 6.06 |
| Long Term Debt | 225.17 | 111.26 | Not available |
| Common Stock Total | 45.33 | 45.32 | 45.31 |
| Other Equity Total | 2,079.28 | 1,944.59 | 8.06 |
| Other Current Assets Total | 153.61 | 96.82 | 0 |
| Total Assets | 3,481.71 | 2,902.43 | 2,582.11 |
| Current Portof LT Debt/Capital Leases | 16.55 | 5.09 | 4.49 |
| Cash | 1.09 | 1.91 | 24.07 |
| Total Equity | 2,124.6 | 1,989.91 | 1,757.04 |
| Long Term Investments | 229.28 | 43.27 | 36.78 |
| Total Common Shares Outstanding | 9.07 | 9.06 | 9.06 |
| Tangible Book Valueper Share Common Eq | 220.69 | 208.49 | 185.38 |
| Total Liabilities | 1,357.1 | 912.52 | 825.07 |
| Total Debt | 793.72 | 420.82 | 285.25 |
| Short Term Investments | 0 | 48.72 | 76.68 |
| Cashand Short Term Investments | 9.62 | 57.37 | 100.74 |
| Total Receivables Net | 593.76 | 576.42 | 589.31 |
| Notes Payable/Short Term Debt | 499.82 | 292.8 | 264.06 |
| Deferred Income Tax | 134.33 | 128.4 | 107.92 |
| Accounts Receivable-Trade Net | 583.32 | 575.4 | 519.34 |
| Property/Plant/Equipment Total-Net | 1,706.66 | 1,410.7 | 1,093.19 |
| Total Current Liabilities | 937.57 | 653.07 | 694.39 |
| Total Inventory | 640.31 | 587.58 | 649.44 |
| Accounts Payable | 334.54 | 277.83 | 378.32 |
| Other Currentliabilities Total | 86.66 | 77.35 | 32.26 |
| Total Long Term Debt | 277.35 | 122.93 | 16.7 |
| Intangibles Net | 123.89 | 98.44 | 75.27 |
| Other Long Term Assets Total | 16.81 | 22.75 | 11.33 |
| Note Receivable-Long Term | 7.78 | 7.3 | 18.11 |
| Total Current Assets | 1,397.29 | 1,318.19 | 1,345.64 |
| Capital Lease Obligations | 52.18 | 11.67 | 16.7 |
| Property/Plant/Equipment Total-Gross | Not available | 322.01 | 1,630.04 |
| Goodwill Net | Not available | 1.78 | 1.78 |
| Accumulated Depreciation Total | Not available | Not available | -536.85 |
| Accrued Expenses | Not available | Not available | 15.26 |
| Prepaid Expenses | Not available | Not available | 6.15 |
| Additional Paid-In Capital | Not available | Not available | 440.33 |
| Retained Earnings(Accumulated Deficit) | Not available | Not available | 1,263.34 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %755.71
Margins
Operating Margin 12m16.23
Operating Margin 5y Avg17.76
Net Profit Margin 12m10.25
Net Profit Margin 5y10.97
Yield
Dividend Yield %0.51
Valuation
Price to Sale Ratio3.46
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk40.62
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 42.86%
- FII
- 8.17%
- MF
- 0.79%
- Other
- 48.18%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Aarti Pharmalabs Yearly results, Financial Summary - The Economic TimesMarket news · 4 Jun 2026, 10:21 pm
Aarti Pharmalabs Yearly results, Financial Summary The Economic Times
Aarti Pharmalabs Ltd is Rated Sell - Markets MojoMarket news · 2 Jun 2026, 2:59 am
Aarti Pharmalabs Ltd is Rated Sell Markets Mojo
Buy, sell or hold: Hitachi Energy, Union Bank, Aarti Pharmalabs, Coal India, Petronet, Balaji Amines — Ask Profit - MSNMarket news · 1 Jun 2026, 3:45 pm
Buy, sell or hold: Hitachi Energy, Union Bank, Aarti Pharmalabs, Coal India, Petronet, Balaji Amines — Ask Profit MSN
Aarti Pharmalabs targets 15-18% revenue and EBITDA growth over 3-4 years - scanx.tradeMarket news · 1 Jun 2026, 12:30 pm
Aarti Pharmalabs targets 15-18% revenue and EBITDA growth over 3-4 years scanx.trade
Aarti Pharmalabs Insider Ups Holding During Year - simplywall.stMarket news · 1 Jun 2026, 7:36 am
Aarti Pharmalabs Insider Ups Holding During Year simplywall.st
Aarti Pharmalabs Ltd (BOM:543748) Q4 2026 Earnings Call Highlights: Revenue Growth Amidst ... By GuruFocus - Investing.com CanadaMarket news · 30 May 2026, 8:55 am
Aarti Pharmalabs Ltd (BOM:543748) Q4 2026 Earnings Call Highlights: Revenue Growth Amidst ... By GuruFocus Investing.com Canada
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.2.0000 per share(40%)Final Dividend
- board Meetings(Revised)
- board MeetingsAudited Results & Final Dividend
- dividendRs.1.5000 per share(30%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Aarti Pharmalabs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. The Company's products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- AARTIPHARM
- BSE Code
- 543748
Questions
Stock FAQ
What is the symbol and ISIN of Aarti Pharmalabs?
Aarti Pharmalabs has the symbol AARTIPHARM and ISIN - INE0LRU01027.
What is the current price of Aarti Pharmalabs?
Aarti Pharmalabs is currently trading at INR 812.45.
What are the year high and year low of Aarti Pharmalabs?
Aarti Pharmalabs has a year high of INR 946.10 and a year low of INR 585.00.
What is the market capitalization of Aarti Pharmalabs?
Aarti Pharmalabs has a market capitalization of INR 6,302.24 crore.
What is the P/E ratio of Aarti Pharmalabs?
Aarti Pharmalabs has a P/E ratio of 28.53.
What is the dividend yield of Aarti Pharmalabs?
Aarti Pharmalabs has a dividend yield of 0.51%.
How is the financial performance of Aarti Pharmalabs based on revenue, net income, and EPS?
Aarti Pharmalabs has revenue of INR 1,819.44 crore, net income of INR 174.71 crore, and EPS of INR 20.81.
What is the book value of Aarti Pharmalabs?
Aarti Pharmalabs has a book value of INR 220.69.
What is the debt-to-equity ratio of Aarti Pharmalabs?
Aarti Pharmalabs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Aarti Pharmalabs?
Aarti Pharmalabs has a price-to-book ratio of 3.68 and a price-to-sales ratio of 3.46.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.